Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR., Bethel MA., Chan JCN., Chiasson J-L., Doran Z., Ge J., Gerstein H., Huo Y., McMurray JJ., Ryden L., Liyanage W., Schröder S., Tendera M., Theodorakis MJ., Tuomilehto J., Yang W., Hu D., Pan C., ACE Study Group None.
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.